tirzepatide 16.6 mg ml Dosing for Weight Loss in Units Lilly releases Zepbound® (tirzepatide) single-dose

Multiple clinical trials funded by Novo Nordisk show semaglutide can reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults with Type 2 diabetes and known heart disease

Individuals already taking GLP-1 receptor agonists for diabetes or weight management should continue their prescribed therapy as directed, but should not expect guaranteed cognitive benefits beyond those associated with improved metabolic health

Patient should also be aware of how to source medication from private provider who are regulated and registered with the General Pharmaceutical Council

A 2021 study published in the New England Journal of Medicine showed that people on semaglutide lost 14.9% of their body weight over 68 weeks versus 2.4% in the placebo group